Albireo Pharma (ALBO) Prices 1.905M Share Common Offering at $21/Sh

Albireo Pharma, Inc. (NASDAQ: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share. Albireo’s gross proceeds from this offering are expected to be approximately $40 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Albireo has granted the underwriters a 30-day option to purchase up to an additional 285,750 shares of common stock on the same terms and conditions. All of the shares in the offering are being sold by Albireo. The offering is expected to close on or about February 3, 2020, subject to customary closing conditions.

Jefferies is acting as the sole book-running manager and representative of the underwriters for the offering.

You May Also Be Interested In

• QNB Corp. overallotment option adds 160,714 shares at $42 each
• Aveanna selling stockholders launch 15M share secondary offering
• BKV Corporation (BKV) files for 5.315M share offering by selling stockholders